Exploring human milk oligosaccharides and malaria risk in breastfed infants

探索母乳低聚糖和母乳喂养婴儿的疟疾风险

基本信息

  • 批准号:
    10226366
  • 负责人:
  • 金额:
    $ 17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-01 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT There is a significant burden of malaria in young African infants - the majority of whom are breastfed from birth up to 24 months. These `break through' malaria infections probably indicate incomplete protection by breastfeeding. There is a significant gap in our knowledge about antimalarial immunity mediated by breastfeeding and the factors involved. Our recent preliminary data demonstrated that high concentrations of specific human milk oligosaccharides (HMOs) in Ugandan mothers' milk are differentially associated with malaria risk in their infants. HMOs represent the third most abundant component in breast milk which, upon ingestion by infants, reach the systemic circulation where they directly engage innate immune cells through specific surface receptors. Studies involving ex vivo stimulation of human cells and cell lines demonstrated that HMOs modulate the functions of macrophages and monocytes in several ways. This includes inducing anti-inflammatory or proinflammatory responses, inducing or inhibiting monocyte or macrophage activation, inhibition of proliferation or migration, and enhancing phagocytosis. A human clinical trial involving infants fed 2'- fucosyllactose (2'FL) in formula confirmed the anti-inflammatory effect of 2'FL. HMO-mediated modulation of monocyte function is highly relevant to pediatric malaria which involves monocyte dysregulation and systemic inflammation. Our long-term goal is to elucidate the role of HMOs in early innate immunity against malaria. The objective of this project is to determine the relationship between HMOs in breast milk and infant blood, monocyte function, and malaria outcomes in breast-fed infants. The central hypothesis is that direct HMO modulation of monocytes tips the balance towards disease or protection during pediatric malaria and that differences in levels of specific HMOs are linked to different malaria outcomes. This hypothesis will be tested in two Specific Aims. Aim 1: To recruit a birth cohort and prospectively collect health metadata including malaria outcomes and concentrations of soluble monocyte activation markers, cytokines and chemokines in infants. A birth cohort of 388 mother-infant pairs will be recruited and infants followed over 18 months with blood sampling every month and during infant illness for malaria diagnosis, multiplex bead-based cytokine and chemokine assays and ELISA for soluble monocyte activation markers. Aim 2: To measure concentrations of HMOs in mothers' milk and infant plasma to assess their association with monocyte mediators and malaria outcomes in infants. We will measure concentrations of HMOs in mothers' milk and infant plasma monthly and during pediatric malaria attacks to identify HMOs that are associated with specific monocyte inflammatory cytokines and chemokines and activation markers which are, in turn, linked to distinct malaria outcomes. To account for correlation between multiple measurements in the same infant, the relationships between malaria outcomes, specific HMOs, and markers of monocyte function will be assessed by Generalized Estimating Equation method while controlling for covariates such as maternal age and parity, infant sex, season of sampling and other malaria risk factors. The team brings experience in malaria and HMO research plus access to a study population in Uganda. Together, these proposed exploratory studies will provide preliminary insights on the crucial role that HMOs play in malaria innate immunity. This project will set the stage for more powered mechanistic studies of HMO-monocyte interactions which will inform the design of novel antimalarial interventions. The results are generalizable to other regions with a high burden of malaria in young infants. The potential to move the field forward and make a sustainable impact is high.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lars Bode其他文献

Lars Bode的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lars Bode', 18)}}的其他基金

Origins and Benefits of Biologically Active Components in Human Milk
母乳中生物活性成分的来源和益处
  • 批准号:
    10683486
  • 财政年份:
    2023
  • 资助金额:
    $ 17万
  • 项目类别:
Milk Analytics Core
牛奶分析核心
  • 批准号:
    10487510
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
利用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素
  • 批准号:
    10681290
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:
Milk Analytics Core
牛奶分析核心
  • 批准号:
    10681304
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:
Exploring Associations between Human Milk Oligosaccharides and Atherosclerosis Risk Factors in Infancy and Early Childhood
探索母乳低聚糖与婴儿期和幼儿期动脉粥样硬化危险因素之间的关联
  • 批准号:
    10491367
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:
Exploring Associations between Human Milk Oligosaccharides and Atherosclerosis Risk Factors in Infancy and Early Childhood
探索母乳低聚糖与婴儿期和幼儿期动脉粥样硬化危险因素之间的关联
  • 批准号:
    10195374
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
利用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素
  • 批准号:
    10659295
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
利用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素
  • 批准号:
    10309708
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:
Milk Analytics Core
牛奶分析核心
  • 批准号:
    10309713
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
利用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素
  • 批准号:
    10487493
  • 财政年份:
    2021
  • 资助金额:
    $ 17万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 17万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 17万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 17万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 17万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 17万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 17万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 17万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 17万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 17万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了